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Summary
There are substantial advances in understanding disordered gastrointestinal
autonomic dysfunction in diabetes. It occurs frequently. The underlying
pathogenesis is complex involving defects in multiple interacting cell types of
the myenteric plexus as well. These defects may be irreversible or reversible.
Gastrointestinal symptoms represent a major and generally underestimated
source of morbidity for escalating health care costs in diabetes. Acute
changes in glycaemia are both determinants and consequences of altered
gastrointestinal motility. 35–90% of diabetic men have moderate-to-severe
erectile dysfunction (ED). ED shares common risk factors with CVD. Diagnosis
is based on medical/sexual history, including validated questionnaires.
Physical examination and laboratory testing must be tailored to patient’s
complaints and risk factors. Treatment is based on PDE5-inhibitors (PDE5-
I). Other explorations may be useful in patients who do not respond
to PDE5-I. Patients at high cardiovascular risk should be stabilized by
their cardiologists before sexual activity is considered or ED treatment is
recommended.
Estimates on bladder dysfunction prevalence are 43–87% of type 1 and 25%
of type 2 diabetic patients, respectively. Common symptoms include dysuria,
frequency, urgency, nocturia and incomplete bladder emptying. Diagnosis
should use validated questionnaire for lower urinary tract symptoms. The type
of bladder dysfunction is readily characterized with complete urodynamic
testing.
Sudomotor dysfunction is a cause of dry skin and is associated with foot
ulcerations. Sudomotor function can be assessed by thermoregulatory sweat
testing, quantitative sudomotor axon reflex test, sympathetic skin response,
quantitative direct/indirect axon reflex testing and the indicator plaster.
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Abbreviations AGE – advanced glycation end products; BPH – benign pro-
static hyperplasia; CAN – cardiovascular autonomic neuropathy; cGMP –
cyclic guanosine monophosphate; CVD – cardiovascular disease; DPN –
diabetic polyneuropathy; DBSQ – Diabetes Bowel Symptom Question-
naire; GIP – gastro inhibitory polypeptide; GLP – glucagon-like pep-
tide; HRV – heart rate variability; ICC – interstitial cells of Cajal;
LDF – laser Doppler flowmetry; LDPI – laser Doppler perfusion imag-
ing; LSCI – laser speckle contrast imaging; LUTS – lower urinary tract
symptoms; MBF – microvascular blood flow; NOS – nitric oxide syn-
thase; PDE5-I – phosphodiesterase type 5 inhibitor; PGE1 – prostaglandin
E1; PMN – polymorphonuclear leukocyte; PVR – postvoid residual vol-
ume; QDIRT – quantitative direct and indirect axon reflex testing;
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QoL – quality of life; QSART – quantitative sudomotor
axon reflex test; RCT – randomized controlled trial;
SFN – small fibre neuropathy; SSEP – somatosensory-
evoked potentials; SSR – sympathetic skin response;
TST – thermoregulatory sweat testin
Introduction
In this article, gastrointestinal, erectile, bladder and
sudomotor dysfunction are reviewed. Disorders such as
neuroarthropathy, hypoglycaemia unawareness, neuro-
pathic oedema and pupillary abnormalities, which are in





Disordered gastrointestinal motility in diabetes may be
associated with gastrointestinal symptoms, impaired oral
drug absorption, poor glycaemic control, malnutrition
and abnormal postprandial regulation of blood pressure.
Reports on the prevalence of gastrointestinal symptoms
and disordered motility in diabetes are inconsistent
reflecting, partly, variations in methodology and the
populations studied. Gastrointestinal symptoms impact
negatively on health-related quality of life and women
appear to be affected more frequently. The relationships
among symptoms, disordered gastrointestinal motility
and CAN are relatively weak.
Oesophageal transit, as measured using radionuclide
techniques, is delayed in ∼50% of patients with
longstanding diabetes, but does not correlate closely with
delayed gastric emptying [1]. Other than acid reflux,
oesophageal dysfunction can result in regurgitation,
dysphagia and a propensity for pill-induced oesophageal
erosions and structures.
Gastroparesis, defined as a delayed gastric emptying in
the absence of an obstructive aetiology, is arguably the
most important manifestation of gastrointestinal auto-
nomic neuropathy affecting about 30–50% of outpatients
with longstanding type 1 or type 2 diabetes [1,2]. The
prevalence is highest when gastric emptying of both
solids and nutrient-containing liquids is quantified [1,2].
Abnormally rapid gastric emptying was also described in
diabetes [3]. Symptoms of gastroparesis usually relate
to impaired gastric relaxation and ‘hypersensitivity’ to
gastric distension. Only postprandial fullness appears to
be a significant predictor of delayed gastric emptying
of solids. Symptoms attributable to gastroparesis are
reported in 5–12% of diabetic patients in the commu-
nity, but higher rates are evident in patients evaluated
in tertiary referral centres [4]. Symptoms seem to be
more common in those with poor chronic glycaemic
control, while acute hyperglycaemia has been shown
to increase the perception of gastrointestinal sensations.
Symptoms occur more frequently in patients with mark-
ers of psychological disorders. Symptom ‘turnover’ occurs
frequently [2]. While patients with symptomatic gastro-
paresis utilize substantially more healthcare resources
than diabetic patients without gastroparesis, moderate
gastroparesis does not appear to be a rapidly progres-
sive disease and is not associated with poor adverse
prognosis [2].
Gastric emptying rate is of fundamental importance
to postprandial glycaemia, accounting for at least a
third of the variance of the initial rise, as well
as the peak blood glucose response to carbohydrate-
containing meals in healthy subjects, and patients with
type 1 and type 2 diabetes. Gastric emptying rate is
also a determinant of the incretin hormone responses
which further affect postprandial glycaemia [5,6]. Even
minor changes in the rate of carbohydrate delivery
to the small intestine can have a substantial effect
on glycaemia [6]. In insulin-treated patients nutrient
delivery needs to be matched with the action of
exogenous insulin and delayed gastric emptying has
recently been documented as an important cause of
otherwise unexplained hypoglycaemia – a phenomenon
called ‘gastric’ hypoglycaemia [7]. In contrast, in type
2 diabetic patients not treated with insulin, a delayed
carbohydrate absorption is often beneficial for glycaemic
control.
Diabetes is also associated with a high prevalence
of disordered small and large intestinal, and anorectal
motility [8]. Either delayed or rapid small intestinal
transit may be observed and may influence carbohydrate
absorption. Diarrhoea is reported by up to 20% of
patients and may reflect rapid or slow transit, frequently
complicated by bacterial overgrowth. There is little
information about colonic function in diabetes, but
constipation has been reported in up to 60% of patients
with longstanding diabetes [8]. An increased prevalence
of faecal incontinence, particularly nocturnal, is related
to reduced and unstable internal anal sphincter tone,
impaired rectal compliance and sensation.
Pathogenesis
Gastrointestinal motor, sensory and secretory functions
are modulated by the interaction of autonomic and enteric
nervous systems with underlying rhythmicity generated
by the so-called ICC located within the smooth muscle.
The autonomic nervous system provides extrinsic inner-
vation of gut function, via parasympathetic (vagal and
pelvic) and sympathetic (mesenteric) nerves. Parasympa-
thetic innervation is both excitatory (cholinergic) and
inhibitory (non-adrenergic, non-cholinergic), whereas
sympathetic input is generally inhibitory, with the excep-
tion of the lower oesophageal and anal sphincters. The
pathogenesis of gastrointestinal ‘autonomic neuropathy’
is now recognized to be complex and multifactorial with
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defects in various interacting cell types and potentially,
reversible, functional abnormalities, in addition to the
more established roles of autonomic neuropathy and acute
hyperglycaemia.
Data from the NIH-funded Gastroparesis Clinical
Research Consortium have contributed significantly to
knowledge of the role of cellular defects underlying dis-
ordered gut function, particularly the pathogenesis of
gastroparesis. Documented changes include reduced num-
bers of ICC, deficiencies of inhibitory neurotransmission,
reduced numbers of extrinsic autonomic neurons and
smooth muscle [9]. Loss of dysfunction of ICC appears
to be central to the pathogenesis of diabetic gastroparesis
[10]. In animal models and humans with diabetic gastro-
paresis, a reduction in intraneuronal levels of nitric oxide
has been observed.
Acute variations in glycaemia have a major impact
on gut motor function in both healthy and diabetic
subjects [5]. In type 1 patients, marked hyperglycaemia
(16–20 mmol/L) slows gastric emptying of solids and
nutrient-containing liquids substantially. Even within the
physiological postprandial glycaemic range, the rate of
gastric emptying is slower at a blood glucose of 8 mmol/L
than 4 mmol/L, in healthy subjects and patients with
uncomplicated type 1 diabetes [11]. In contrast, insulin-
induced hypoglycaemia accelerates gastric emptying even
in type 1 patients with gastroparesis. Hyperglycaemia also
increases the perception of gastrointestinal symptoms
in patients with diabetes [12]. Potential mediators
of the effects of glycaemia on gut motility include
impaired vagal function, altered prostaglandin synthesis,
changes in nitric oxide mechanisms and both central
and peripheral glucose-responsive neurons. The effects of
variations in glycaemia in type 2 diabetes are less well
documented.
Diagnosis
Studies of the autonomic neuropathy in diabetes, whether
performed for clinical, epidemiological or research pur-
poses, may potentially focus on gastrointestinal symp-
toms, QoL, gastrointestinal motility/transit, glycaemic
control and/or postprandial blood pressure. A num-
ber of measurements are available to quantify gas-
trointestinal symptoms, including the DBSQ, which has
been validated in a diabetic population. QoL measures
have not focused specifically on the gastrointestinal
tract.
Due to the poor predictive value of symptoms, objective
measurements of gastric emptying are advocated for the
diagnosis of gastroparesis. Evaluation of solid emptying is
probably more sensitive than that of low-nutrient liquid
or semi-solid meals. However, some patients will only
exhibit delay to liquid meals. Gastric emptying can be
affected acutely by many factors, including medications,
smoking and blood glucose concentrations. Other causes
of gastroparesis must be excluded. Medications that may
influence gastric emptying should ideally be withdrawn
for 48–72 h prior to the test, smoking should be avoided
on the test day and the blood glucose concentration should
be monitored and ideally be >4 and <10 mmol/L during
the test [11]. Failure to demonstrate delayed gastric
emptying need not imply that symptoms are not due
to ‘diabetic gastropathy’.
Scintigraphy is still regarded as the ‘gold standard’
technique for measurement of gastric emptying. The
intragastric distribution of a meal, which is frequently
abnormal in diabetic patients, can also be evaluated.
The level of standardization of the technique between
centres is a major limitation, rectified to some extent
by recent ‘consensus’ guidelines which recommend a
low-fat, egg white meal labelled with 99 mTc sulfur
colloid and consumed with jam and toast as a sandwich,
with a glass of water [2]. If carbohydrate is included
in the meal the relationship between glycaemic response
and gastric emptying rate can be evaluated [1]. The
limitations of scintigraphy are exposure to a modest
dose of radiation, the relative expense and the need
for specialist centres.
Breath test results using non-radioactive 13C-acetate
or -octanoic acid as a label are safe, inexpensive and
correlate well with scintigraphy results [2,13].
Ultrasonography is a non-invasive diagnostic method
and two-dimensional ultrasound has been validated
for measuring emptying of liquids and semi-solids.
Three-dimensional ultrasound offers, however, a more
comprehensive imaging of the total stomach. Magnetic
resonance imaging has been used to measure gastric
emptying and motility with excellent reproductivity,
but its use is limited to research purposes. Surface
electrogastrography should be considered currently as
a research tool. A barium meal has a place in evaluating
mucosal lesions or obstruction. Pressure measurements
assessing motor function of the stomach, small intestine
and colon correlate relatively well with scintigraphy
results [13]. Manometry should be considered as a
research technique to investigate gastric and intestinal
motility. Tests of anorectal motor and sensory functions
are well developed for clinical use.
Management
Gastrointestinal symptoms
The management of patients with symptomatic diabetic
gastrointestinal autonomic neuropathy should focus on
relief of gastrointestinal symptoms, improvement in
nutritional status and optimization of glycaemic control.
Patients with type 1 diabetes may benefit from insulin
pump therapy.
Patients with disordered oesophageal motility asso-
ciated with reflux should be managed conventionally,
usually with proton pump inhibitors. Fluids should be
consumed immediately after medications to minimize the
possibility of pill-induced oesophagitis.
In patients with symptomatic gastroparesis, low-
fat/fibre diets are frequently advocated, but their use is
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empirical. Prokinetic drugs, including metoclopramide,
erythromycin and domperidone, are the mainstay of
treatment. Their effect is due to the stimulation
of acetylcholine release in the myenteric plexus to
dopamine antagonist properties or by stimulating motilin
receptors in the gut. The acceleration of gastric
emptying by prokinetics is greater if baseline emptying
is more delayed and their effect is attenuated during
acute hyperglycaemia [14]. In a systematic analysis of
clinical trials comparing various prokinetics, erythromycin
appeared to be superior in accelerating gastric emptying
and relieving symptoms [15], but its long-term efficacy
is limited by tachyphylaxis due to down-regulation of
motilin receptors, gastrointestinal adverse effects and,
possibly, an increased risk of cardiac death. The adverse
effects of the central nervous system are common and
irreversible tardive dyskinesia is a rare complication with
the use of metoclopramide. Domperidone is also effective
at relieving symptoms and may now be regarded as the
current ‘first-line’ agent, subsequent to restrictions in the
availability of cisapride due to arrhythmias related to QT
interval prolongation. Several drugs, including the motilin
agonist, mitemcinal, ghrelin and ghrelin receptor agonists,
5HT4-receptor agonists and the muscarinic antagonist,
acotiamide, are being currently investigated for their
potential use [10]. Non-pharmacological treatments
for diabetic gastroparesis are available. High-frequency
gastric electrical stimulation with the Enterra device has
been used widely, study results are controversial and
have failed to provide conclusive evidence of benefit [16].
Benefits of surgical therapy for intractable gastroparesis
remain uncertain. Uncontrolled observations support
the benefit of pancreatic transplantation on gastric
emptying.
The management of diarrhoea, constipation and
faecal incontinence is still largely symptomatic once
specific causes like coeliac disease and exocrine
pancreatic insufficiency are excluded [17]. Bacte-
rial overgrowth, implicated in up to 40% of dia-
betic patients with chronic diarrhoea, should be
treated with antibiotics. Patients with accelerated tran-
sit or faecal incontinence may respond to loperamide,
which slows small and large intestinal transit and
increases internal anal sphincter tone [17]. In cases
of severe diarrhoea somatostatin analogues may be
effective.
Glycaemic control
The novel insights relating to the impact of gastric emp-
tying on glycaemia have stimulated the development
of dietary and pharmacological strategies to improve
glycaemic control by modulating gastric emptying. The
relationship of glycaemia to small intestinal carbohy-
drate delivery is now recognized to be nonlinear, as
evidenced by the glycaemic response to intraduodenal
infusion of glucose at rates within the normal range for
gastric emptying in healthy and type 2 diabetic patients.
Non-pharmacological strategies include dietary modifi-
cations to slow gastric emptying by increasing dietary
fibre and the use of fat or protein ‘preloads’ taken before
a meal [18]. The rationale for the latter approach is
to slow gastric emptying by stimulating small intestinal
neurohumoral feedback mechanisms and the release of
GIP and GLP-1 before the main meal. Slowing of gastric
emptying may be the predominant mechanism by which
exogenous GLP-1 and its analogues reduce postprandial
glycaemia. The magnitude of slowing gastric emptying by
exenatide is most marked when gastric emptying is more
rapid and seems not to be attenuated by the presence of
CAN [19].
Postprandial hypotension occurs frequently in diabetes
(probably more commonly than orthostatic hypotension).
The magnitude of the fall in blood pressure is related
directly to the rate of gastric emptying when small
intestinal carbohydrate delivery is more rapid, and the
fall in blood pressure is greater. Dietary pharmacological
strategies slowing gastric emptying and reducing small
intestinal carbohydrate absorption are likely to prove
effective in the management and there is evidence that the
α-glucosidase inhibitor, acarbose, may be useful. Delayed
gastric emptying influences the delivery and absorption of
orally administered drugs in the small intestine, resulting
in later, or fluctuating maximal serum concentrations.
This is particularly important if rapid onset drug action is
required.
Summary and recommendations
During the past 25 years there has been a substan-
tial redefinition of concepts relating to the prevalence,
clinical significance, pathogenesis and management of
‘gastrointestinal autonomic neuropathy’ in diabetes. The
pathogenesis is now recognized to be complex and het-
erogeneous. Gastrointestinal symptoms occur frequently
in diabetes and affect QoL adversely. Diabetes is the most
common cause of chronic gastroparesis affecting 30–50%
of patients with longstanding diabetes and the rate of
gastric emptying is a major determinant of postpran-
dial glycaemia. Management is frequently suboptimal and
should focus on the relief of gastrointestinal symptoms as
well as improvement in nutritional status and glycaemic
control.
1. Inquire routinely about gastrointestinal symp-
toms (C).
2. Measure gastric emptying, by either scintigraphy or
stable isotope breath test, in patients with suspected
gastroparesis (B).
3. Initiate therapy with a prokinetic drug and optimize
glycaemic control in patients with symptomatic
gastroparesis (B).
4. Recognize that gastroparesis may impact adversely
on glycaemic control, particularly in insulin-treated
patients (C).
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Erectile dysfunction
Definition
Erectile dysfunction is defined as persistent inability to
achieve or maintain an erection sufficient to permit
satisfactory sexual intercourse. Normal penile erection
is the result of a hemodynamic process and is depen-
dent on corporal smooth muscle relaxation mediated by
parasympathetic neurotransmission, nitric oxide, electro-
physiologic events and other regulatory factors.
Epidemiology
Erectile dysfunction prevalence among diabetic men
varies from 35 to 90% depending mainly on the popula-
tion studied and various methods applied. In a nationally
representative study from managed care claims in the US
database, diabetes prevalence rates were 20.0% in men
with erectile dysfunction and 7.5% in men without erec-
tile dysfunction [20]. The Cologne Male Survey noted a
fourfold increase in erectile dysfunction in men with dia-
betes compared to the general population. The presence
of diabetes was associated with an odds ratio for erec-
tile dysfunction by 3.95 (2.98–5.23). Erectile dysfunction
prevalence in the younger age groups (40–60 years) with
diabetes was as high as in the older groups of non-diabetic
subjects (60–80 years). In another survey, erectile dys-
function frequency among diabetic men aged 45–49 years
was similar to that in non-diabetic men aged over 70 years
[21]. In the EURODIAB IDDM Complications Study [22],
16% of patients (range: 2–35%) had problems with inter-
course, 16% (range: 2–85%) had problems obtaining an
erection, 18% (range: 2–83%) had problems sustaining
an erection, while 35% (range: 23-84%) had reported
not to have erections at night or in the morning. Among
713 men with type 1 diabetes participating in the Diabetes
Control and Complication Trial/Epidemiology of Diabetes
Interventions and Complications Study (DCCT/EDIC),
erectile dysfunction was present in 34%, orgasmic dys-
function in 20% and decreased libido in 55% at year
10 of Epidemiology of Diabetes Interventions and Com-
plications Study follow-up and after a mean diabetes
duration of the cohort of 22.1 years [23]. The crude inci-
dence rate of erectile dysfunction in the Massachusetts
Male Aging Study was 26 cases/1000 man-years in 847
men aged 40–69 without erectile dysfunction at base-
line, who were followed for an average of 8.8 years [24].
The age-adjusted erectile dysfunction risk was higher for
men with lower education, diabetes, heart disease and
hypertension. Erectile dysfunction incidence rate in dia-
betic men was increased twofold, with 50 cases/1000
man-years. In a study from Italy that included 9868 men
with diabetes, 45.5% of those aged >59 years reported
erectile dysfunction. Risk factors and clinical correlates
included the following (odds ratio [95% CI]): autonomic
neuropathy (5.0 [3.9–6.4]), diabetic foot (4.0 [2.9–5.5]),
peripheral neuropathy (3.3 [2.9–3.8]), peripheral arte-
rial disease (2.8 [2.4–3.3]), nephropathy (2.3 [1.9–2.8]),
poor glycaemic control (2.3 [2.0–2.6]), retinopathy (2.2
[2.0–2.4]), hypertension (2.1 [1.6–2.9]) and diabetes
duration (2.0 [1.8–2.2]) [25]. However, even when neu-
ropathic complications are present, psychiatric illnesses
may be important contributors to erectile dysfunction in
diabetic men. The aetiology of psychogenic erectile dys-
function includes anxiety, depression, sexual phobias and
stress. Thus, psychogenic components must not be over-
looked. The key differences between psychogenic and
organic erectile dysfunction are shown in Table 1.
Erectile dysfunction is a well-recognized index of car-
diovascular risk and an independent predictor of coronary
artery disease. Prospective studies have shown that erec-
tile dysfunction predicts the development of CVD [26]
and CVD mortality [27]. The risk of CVD associated with
erectile dysfunction is in the range of risk associated
with traditional CVD risk factors [27,28], such as current
smoking, hypertension or family history of myocardial
infarction, but erectile dysfunction does not improve the
prediction of who will and will not develop CVD beyond
that offered by traditional risk factors. New onset or
progressive decline in erectile dysfunction should be con-
sidered as an alarming marker of threatening ischaemic
heart disease even at asymptomatic stages.
Erectile dysfunction correlates significantly with the
severity of CAN among type 1 diabetic patients. Although
erectile dysfunction is associated with autonomic neu-
ropathy, erectile dysfunction prevalence in patients with
CAN and the prevalence of CAN among patients with
erectile dysfunction have not been analysed in large epi-
demiological studies.
Longitudinal studies are essential to assess the natural
course of erectile dysfunction. In a 1-year longitudinal
study [28], the health-related quality of life and erectile
dysfunction severity were compared in men with and
without the history of diabetes. Diabetic men with a newly
started erectile dysfunction treatment had favourable
results at 6 months, but the response to therapy was
not durable. In the study [29] with the highest number
of participants’ (n = 1456) deterioration in QoL just as
worsening of depressive symptoms preceded the onset of
erectile dysfunction.
Pathogenesis
The prominent role of neuropathy in the pathogen-
esis of erectile dysfunction is mainly explained by
decreased smooth muscle relaxation of the corpus cav-
ernosum and insufficient NOS function. The impaired
sensation of the glans and abnormal motor function
of muscles participating in erection also contribute to
erectile dysfunction development among patients with
neuropathy. Erectile dysfunction pathogenesis in dia-
betes is multifactorial, related to neuropathy, accelerated
atherosclerosis and alterations in the corporal erectile
tissue, including smooth muscle degeneration, abnormal
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Table 1. The classification of erectile dysfunction: psychogenic or organic?
Aetiology Psychogenic Organic
Onset Sudden onset Gradual onset
Initiation Complete immediate loss Incremental progression
Morning erection Morning erections present Lack of morning erections
Presence or absence under certain
circumstances
Varies with partner and circumstance Lack of erections under most sexually
stimulating circumstances
collagen deposition and endothelial cell dysfunction. AGE
have been shown to quench NO and to be elevated in
human diabetic penile tissue.
Diagnosis
Good clinical history and physical examination are the
basis of assessment. It is important to establish the
nature of the erectile problem and to distinguish it from
other forms of sexual difficulty such as penile curva-
ture or premature ejaculation. An interview with the
partner is advisable and will confirm the problem but
may also reveal other causes of difficulties, e.g. vagi-
nal dryness. The relative importance of psychological
and organic factors may be determined from the history.
Drugs associated with erectile dysfunction include tran-
quillizers, antidepressants (tricyclics, selective serotonin
reuptake inhibitors) and antihypertensives (ß-blockers,
vasodilators, central sympathomimetics, ganglion block-
ers, diuretics, ACE inhibitors). Key diagnostic procedures
of erectile dysfunction include comprehensive history
(sexual, medical, drug use, risk factor assessment and psy-
chosocial factors) [30]. Routine laboratory tests should
include HbA1c, fasting blood glucose and lipid profile. The
necessity of total testosterone (if available: bio-available
or free testosterone instead of total) measurement is cur-
rently discussed, but it is clearly necessary in patients who
do not respond to PDE5-Is. The use of validated question-
naires, such as the International Index of Erectile Function
and the Sexual Encounter Profile, is the most appropri-
ate method to characterize frequency and severity of
erectile dysfunction symptoms. Other explorations that
may be useful in patients who do not respond to PDE5-
Is include evaluations of nocturnal penile tumescence,
penile Doppler ultrasound, bulbo-cavernosus reflex, dor-
sal sensory nerve conduction of the penis, amplitude and
latency of penile SSR, pudendal nerve SSEP, assessment
of the effect of PGE1 on erection, psychological evalua-
tion and urodynamic studies. Cardiac risk factors should
be evaluated and managed in all erectile dysfunction
patients. Three risk categories were established at the
first and second Princeton Consensus Conferences [31].
After categorization of patients, an algorithm should be
followed according to individualized risk stratification. As
a first step sexual function assessment and initial cardio-
vascular evaluation are recommended. The second step is
to initiate or resume sexual activity or indicate treatment
of erectile dysfunction in low-risk patients. Patients at
high risk should be stabilized by cardiological treatment
before sexual activity is considered or erectile dysfunc-
tion treatment is recommended. The third step involves
seeking all further risk factors of atherosclerosis in the
presence of erectile dysfunction.
Management
A stepwise therapeutic approach for erectile dysfunction
recently suggested by the European Association of Urology
is shown in Figure 1 [32]. Even if the cause is organic,
almost all men with erectile dysfunction are affected
psychologically. Sexual counselling is an important aspect
of treatment and should also involve the partner. The
initial management should advise the patient to reduce
possible risk factors and optimize glycaemic control.
However, no studies have shown that improvement
in glycaemic control will exert a favourable effect on
erectile dysfunction. Lifestyle modification is associated
with improvement in erectile dysfunction in obese men.
Most men consider oral agents as the first treatment
choice. First-line oral therapy includes PDE5-Is (sildenafil,
vardenafil and tadalafil) [32,33]. The mode of action
of PDE5-Is is delaying of cGMP degradation. Increased
cGMP level leads to decreased intracellular calcium levels,
thereby producing smooth muscle relaxation in corpus
cavernosum and enhancement in blood flow resulting in
erection during sexual stimulus.
Meta-analysis of trials comparing treatment with
various PDE5-Is with placebo in diabetic patients
demonstrates the improvement of erectile dysfunction
in diabetic men without reporting more frequent
cardiovascular adverse events. The use of PDE5-Is
together with oral nitrates is contraindicated. The efficacy
of PDE5-Is is independent of the duration of diabetes,
glycaemic control and microvascular complications. In
diabetic patients the proportion of subjects reporting
improved erection following treatment with any PDE5-I
is lower compared to general population.
Daily use of 2.5 and 5 mg tadalafil for 12 weeks
was well tolerated and significantly improved erectile
dysfunction in diabetic men [34]. However, these studies
lacked an on-demand treatment arm. Daily use of tadalafil
provides an alternative to on-demand dosing for couples
who prefer spontaneous rather than scheduled sexual
activity [32].
Treatment options for patients who do not respond
to PDE5-Is or for whom PDE5-Is are contraindi-
cated include intracavernous injections, intraurethral
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Figure 1. Treatment algorithm for erectile dysfunction in diabetic men (reproduced from Ref. [32])
alprostadil, vacuum constriction devices or penile pros-
thesis implantation [32].
Summary and recommendations
Moderate-to-severe erectile dysfunction is present in
5–20% diabetic men. Erectile dysfunction shares common
risk factors with CVD. Diagnosis is based on medical
and sexual history, including validated questionnaires.
Physical examination and laboratory testing must be
tailored to the patient’s complaints and risk factors.
Treatment is based on PDE5-Is. PDE5-Is have high efficacy
and safety rates in patients with diabetes.
1. Initiate therapy with a PDE5-I in men who seek
treatment for erectile dysfunction, provided there is
no contraindication for PDE5-I use [35] (A).
2. The choice of one specific PDE5-I should be
based on the individual preferences of men with
erectile dysfunction, including ease of use, cost of
medication and adverse effects profile [35] (C).
3. Other choices may be useful in patients who do not
respond to PDE5-Is (B).
4. Routine use of hormonal blood tests or hormonal
treatment in the management of patients with
erectile dysfunctions is not recommended [35] (E).
5. Patients at high cardiovascular risk should be
stabilized by cardiological treatment before the
sexual activity is considered or erectile dysfunction
treatment is recommended (A).
Bladder dysfunction
Diabetes mellitus is associated with an earlier onset and
increased severity of urologic diseases, specifically bladder
disorders. Paralysis of the detrusor muscle, impairment
of bladder sensation, alteration of urothelial receptors
and urothelial signalling mechanisms are the main causes
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of urologic dysfunctions [36]. Diabetic cystopathy has a
significant impact on QoL.
Epidemiology
Longstanding diabetes causes paralysis of the detrusor
muscle leading to voiding difficulties, principally weak
stream, PVR and impairment of bladder sensation.
Estimates on the prevalence of bladder dysfunction
are 43–87% of type 1 diabetic patients and 25% of
type 2 diabetic patients. The correlation between diabetic
cystopathy and peripheral neuropathy ranged from 75 to
100% [37].
Diabetes duration, peripheral neuropathy and retinopa-
thy are significantly associated with severe incontinence.
In women, urinary incontinence is estimated to affect
nearly 50% of middle aged and older women, leading to
significant distress, limitations in daily functioning and
poorer QoL. Diabetes has been identified as an impor-
tant independent risk factor for incontinence in women in
several large observational studies, including the Nurses’
Health Study, and is associated with 30–100% increased
risk. Women with diabetes are more likely to experience
severe and symptomatic urinary incontinence. Type of
incontinence is generally urge incontinence, an involun-
tary loss of urine with a feeling of urgency. Diabetic
women treated with insulin are at considerably higher
risk of urge incontinence than those treated with oral
medications or diet [38].
In men, LUTS are common and often attributed to BPH.
Among men with BPH, diabetes is associated with more
LUTS symptoms compared with non-diabetic men [39].
The effect of diabetes on the development or presence
of LUTS has been studied more in patients with type 1
diabetes and is less clear in type 2 diabetes.
In the Diabetes Control and Complication Trial/
Epidemiology of Diabetes Interventions and Compli-
cations Study cohort, moderate-to-severe LUTS was
reported in nearly 20% of men at year 10 of Epi-
demiology of Diabetes Interventions and Complications
Study follow-up, after a mean diabetes duration of
22.1 years [40]. In the same cohort, among 550 women
with type 1 diabetes who completed a self-administered
questionnaire on incontinence, 38% reported any incon-
tinence and 17% reported weekly or greater incontinence
[41]. Advancing age, increased weight and previous uri-
nary tract infection were associated with higher risk of
incontinence.
Straining, intermittency, postvoid dribbling and weak
stream may be secondary to urethral obstruction from
BPH. However, among men with diabetes, similar
symptoms may also result from bladder dysfunction due
to denervation and poor detrusor contractility
Pathophysiology
Bladder complications in diabetes can be due to an
alteration in the detrusor smooth muscle, neuronal
dysfunction and urothelial dysfunction. Responsiveness
of diabetic bladder strips to externally applied muscarinic
agonists has been reported as increased, decreased or
described as little or no change in responsiveness.
The bladder urothelium is not a passive barrier only,
playing an important role as a sensor, controlling bladder
function. The effects of diabetes on urothelial receptors
and urothelial signalling mechanisms have not been
extensively studied, but it has been well established
that in the streptozotocin-induced diabetic rat model,
there are progressive increases in total bladder tissue
with hypertrophy of the bladder wall and dilation of the
bladder. The urothelial release of prostaglandins, which
sensitize sensory nerves and bladder smooth muscle,
may be increased in diabetes and contribute to some
of the bladder abnormalities (e.g. detrusor overactivity)
observed in diabetic bladder [42].
Clinical evaluation
Common symptoms include dysuria, frequency, urgency,
nocturia and incomplete bladder emptying. Other symp-
toms include infrequent voiding, poor stream, hesitancy
in initiating micturition, recurrent cystitis, stress and
urgency urinary incontinence.
Urge incontinence, defined as involuntary loss of urine
with feeling of urgency, is very frequent in women
with DM, while there was no increased risk of stress
incontinence, defined as involuntary loss of urine with
physical activity.
Evaluation of the diabetic patients should include
specific questions about urinary symptoms, ideally using
a validated questionnaire for incontinence and LUTS.
QoL evaluation by means of specific questionnaires is
also very important. Assessment of perineal sensation,
sphincter tone and the bulbo-cavernosus reflex may
identify peripheral neuropathy consistent with diabetes.
Complete urogynaecologic examination is needed to
exclude pelvic organ prolapse or other pelvic disorders.
Diagnosis
Since diabetic patients are at increased risk of bacterial
cystitis, microscopic urinalysis and culture are essential in
assessing patients complaining of LUTS. The urothelium
in diabetes is susceptible to infections particularly by
Escherichia coli. Alterations in PMN function in high-
glucose state may contribute to an increased risk of
urinary tract infection.
The diagnosis of diabetic neurogenic bladder and
the exact type of dysfunction is made most readily
with complete urodynamic testing. This may include
cystometry, uroflow, simultaneous pressure/flow stud-
ies, sphincter electromyography and urethral pressure
profilometry or evaluation of leak-point pressures. In addi-
tion, electrophysiologic testing or other assessments may
be useful for the assessment of peripheral neuropathy.
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Detailed assessment of bladder function with uro-
dynamic studies is indicated if initial management is
unsuccessful or there is doubt about the diagnosis [38].
Measurement of peak urinary flow rate and PVR should
be considered in diabetic patients with LUTS. PVR should
ideally be measured using portable ultrasound, as inva-
sive catheterization carries a potential risk of infection
[43]. Women with type 2 diabetes have lower maximal
flow rates compared to controls, being most severe in the
presence of peripheral neuropathy [44].
Urodynamic findings include impaired bladder sensa-
tion, increased cystometric capacity, decreased detrusor
contractility and increased PVR.
Diabetic patients who also had gastroparesis had
delayed first sensation, increased capacity and increased
PVR. Cystometric examination may show detrusor
areflexia, but detrusor instability is also frequently
found. Detrusor overactivity is the most common
urodynamic observation (48%) followed by impaired
detrusor contractility (30%), while 15% had poor
compliance [45]. The exact mechanism of the detrusor
overactivity in patients with diabetic cystopathy is unclear.
Changes in bladder functions were observed as early as
within 1 year from the diagnosis of diabetes.
In diabetic children, urinary flow disturbance was
considered as an early sign of autonomic neuropathy
[46]. Children with diabetes had a significantly increased
voiding volume, increased average urinary flow and
increased delay until the first sensation of the need to
void, compared with healthy children. These abnormal
urodynamic features are consistent with sensory nerve
dysfunction. Time to maximum flow is longer in diabetic
subjects as compared with controls and the acceleration
(the ratio of maximum flow and the time to maximum
flow) of diabetic patients is significantly lower. This
decreased acceleration of detrusor muscle contraction
may be interpreted as an early sign of autonomic
neuropathy in diabetic children.
Perineal electrophysiological testing is altered in dia-
betic patients. Electromyography demonstrates peripheral
neuropathy in perineal muscles (urethral striated sphinc-
ter, bulbo-cavernosus muscles). Bulbo-cavernosus reflexes
are altered with an increase in sacral latencies. SSEP of
tibial and pudendal nerves and motor-evoked potentials
after transcranial magnetic stimulation are delayed in
diabetes [47]. Abnormally prolonged tibial SSEP are sta-
tistically correlated with lower urinary tract dysfunction.
On the contrary, abnormality of pudendal SSEP is not
correlated to cystopathy.
Bladder dysfunction has not been assessed up to now
in epidemiological and longitudinal studies or in RCTs.
Summary and recommendations
1. Diabetic cystopathy occurs in up to 80% of type 1
diabetic patients [48] (Class III).
2. Urinary incontinence is strongly associated with
type 1, but not with type 2 diabetes (Class II).
3. Patients with diabetic cystopathy have impaired
detrusor contractions and increased PVR (Class II).
4. Overactive bladder is not uncommon in diabetes,
presumably reflecting both central and peripheral
mechanisms (Class III).
• PVR and urine dipstick (optional culture) should
be performed yearly in all patients with insulin-
dependent diabetes (C) [46].
• Treatment of choice for acontractile bladder
remains intermittent catheterization (B/C) [46].
Sudomotor dysfunction
Epidemiology
Sudomotor function has not yet been assessed in
epidemiological and longitudinal studies or in RCT’s
Pathogenesis
Sweat glands are innervated by sudomotor, postgan-
glionic, thin, unmyelinated cholinergic sympathetic C-
fibres. C-fibres also contribute to MBF regulation. C-fibre
dysfunction can occur early in the course of DPN.
Clinical manifestations
Sudomotor dysfunction is associated with dry skin and
itching and may impair QoL and is associated foot
ulceration in diabetes [49]. In addition, changes in
cutaneous MBF can be associated with adverse changes
in skin quality and structure, foot ulceration and oedema.
Diagnosis
Several methods have been developed to assess sudo-
motor function with variable degree of complexity and
accuracy including TST, QSART, SSR, QDIRT, silicone
impressions and the indicator plaster [50].
TST evaluates the integrity of central and peripheral
sympathetic sudomotor pathways [51]. The core body
temperature is raised to 38 ◦C in a chamber controlled
for humidity and a maximal sweat response recruited
which is detected by a change in the indicator dye
colour. Data are expressed as TST% (anterior body
anhidrosis area/anatomic figure area, ×100). TST cannot
differentiate pre- from postganglionic lesions, is time
consuming, requires special equipment, facilities and
preparation [49,51]. Sensitivity is 91–96% in patients
with distal SFN (Class III) (C) [52]. Data specific to
diabetes are lacking.
The indicator plaster represents a rapid, simple
method based on the colour change of a cobalt II
compound from blue to pink, after 10 min exposure
to dermal foot perspiration at the plantar foot regions
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Table 2. Sensitivity and specificity of the indicator plaster
in detecting peripheral neuropathy and autonomic
neuropathy
Indicator plaster
Authors Sensitivity (%) Specificity (%)
Peripheral neuropathy
Liatis et al. (A) 86 67
Spallone et al. (B) 85 31
Papanas et al. (C) 94 70
Papanas et al. (D) 95 68
Quattrini et al. (E) 85 45
Autonomic neuropathy
Liatis et al. (A) 59 46
Spallone et al. (B) 82 27
Reference are shown as online addendum (Supporting informa-
tion).
[53]. Indicator plaster response correlated [54] with
neuropathy disability score (p < 0.001), neuropathic
symptom score (p = 0.03), cold detection threshold (p =
0.003), heat-as-pain perception threshold (p < 0.043)
and deep-breathing HRV (p < 0.00). Intra-epidermal
nerve fibre density compared with age- and sex-matched
control subjects was significantly reduced in patients
with patchy/absent response (p = 0.02). The authors
concluded that the indicator plaster may serve as a simple
indicator for screening patients with diabetic neuropathy
(C). Indicator plaster results correlate well with the
presence of peripheral sensorimotor neuropathy and to
lesser degree with indications of CAN (Table 2, references
are shown in Supporting information). Although indicator
plaster specificity was lower in most studies, it was
comparable with other established methods (Class II and
III); nonetheless, reference methods were different in the
various studies.
QSART evaluates postganglionic sudomotor function
[52]. Acetylcholine is iontophoresed and sweat produc-
tion measured as an increase in humidity through a
hygrometer [51]. Results are analysed using area under
the curve, maximal sweat production and sweat onset
latency. QSART is unable to detect preganglionic lesions,
requires specialized equipment and is expensive [51].
Sensitivity is 54–90% in patients with SFN (Class III) [52].
Combining QSART with TST improves the sensitivity to
98% and helps to localize the lesion [52]. In patients with
painful diabetic neuropathy, QSART has poor sensitivity
(58%) and correlates with pain severity (Class III) [55].
SSR, surrogate measure of sudomotor function,
measures electrodermal activity [51]. Responses may be
absent in >50-year individuals and there is no clear
definition of abnormal response [51]. A sensitivity of
87.5%, a specificity of 88.2% and a negative predictive
value of 93.7% to diagnose/exclude diabetic autonomic
neuropathy (Class III) is reported [56]. SSR sensitivity
in detecting diabetic (peripheral) neuropathy is 31–76%
(Class III).
Silicone impressions use acetylcholine iontophoresis
to stimulate sweating [51]. QDIRT has been validated
against silicone impressions and QSART [57]. QDIRT
measures the postganglionic sudomotor function [51]
utilizing an indicator dye (alizarin red mixture) and
sweat droplets are quantified [51]. QDIRT is very sensitive
to temperature, humidity, hydration status and caffeine
intake [51]. QDIRT results highly correlate with silicone
images [58].
Microvascular function assessment
The skin offers an accessible organ to assess MBF and
endothelial function, which correlate with systemic mea-
surements of endothelial function and myocardial micro-
circulation [57]. Several methods are available to assess
skin MBF [59]. Laser Doppler allows the determina-
tion of blood flow under baseal conditions or following
physical (e.g. heating) or pharmacological (e.g. acetyl-
choline and/or sodium nitroprusside) stimulation, allow-
ing the differentiation between endothelial-dependent
and -independent responses [57]. Furthermore, laser
Doppler allows the measurement of nerve axon reflex-
related vasodilation following acetylcholine iontophoresis
which is the result of C-fibre stimulation. Laser Doppler
techniques include LDF, LDPI and LSCI [57].
Single-point LDF measures flow within a small volume
of the dermis (1 mm3), while LDPI scans across a larger
area of skin [57]. In LSCI, speckles are formed by the
backscatter of laser light and moving particles cause
fluctuations in the speckle pattern which is related to
the speed of the illuminated particles (such as blood
cells). LDF and LPDI have been utilized in DPN [60], but
data with LSCI are very limited.
LDF has a moderate sensitivity and specificity (75 and
69%, respectively) when compared with SSR in patients
with diabetic (peripheral) neuropathy (Class III) [61].
LDPI has a better performance (sensitivity 92% and
specificity 93%) compared to nerve conduction studies
in diabetic (peripheral) neuropathy (Class III) [62].
In assessing autonomic neuropathy, LDF measurements
showed moderate correlations with CAN parameters.
Each of the above-mentioned laser Doppler techniques
has its advantages/disadvantages. LDF has unacceptably
high variation with the mean day-to-day coefficient of
variation in excess of 30% compared to 6.4–12.1% with
LDPI and 8% with LSCI [60]. The theoretical model link-
ing the outcome measurement to perfusion is well estab-
lished and accepted with regard to LDPI but not for LSCI.
Recommendations
1. All methods mentioned above are appropriate for
sudomotor function testing in diabetic patients,
although some need further validation (Level C).
2. The indicator plaster may serve a simple method
for screening of diabetic (peripheral) neuropathy
(Level C).
3. SSR and QSART performance is better when
detecting autonomic neuropathy compared to
diabetic (peripheral) neuropathy (Level C).
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4. LDPI is a reproducible, sensitive and specific
tool to diagnose diabetic (peripheral) neuropathy
(Level C).
5. There is a need to standardize methods when using
laser Doppler in clinical studies (Level C).
6. Studies validating the use and reproducibility of
LSCI in diabetic (peripheral) neuropathy are needed
(Level C).
7. Prospective studies are needed to assess the
prognostic value of these tests (Level C).
Supporting information
Supporting information may be found in the online
version of this article.
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